Kisspeptin-10

Kisspeptin-10 is a synthetic version of the shortest bioactive fragment of the kisspeptin neuropeptide family, encoded by the KISS1 gene. ^(1,2) The KISS1 gene was originally discovered in 1996 as a metastasis suppressor gene in melanoma research at Penn State (hence the name “KISS” referencing Hershey, Pennsylvania’s famous chocolate “Kisses”). Its role as a critical regulator of reproductive hormones was not identified until 2003, when two independent research groups simultaneously reported that loss-of-function mutations in the kisspeptin receptor (KISS1R/GPR54) cause complete pubertal failure and hypogonadotropic hypogonadism in humans. ^(2,3)

The full-length KISS1 gene product is a 145-amino-acid prepropeptide that is processed into several bioactive C-terminal fragments: kisspeptin-54 (the predominant circulating form, also called metastin), kisspeptin-14, kisspeptin-13, and kisspeptin-10. ^(1,2) All share the same C-terminal decapeptide sequence that confers KISS1R binding. Kisspeptin-10 retains full binding affinity and biological activity at KISS1R, making it the most commonly used variant in research due to its smaller size and synthetic accessibility. ^(1,2)

The discovery that kisspeptin-KISS1R signaling is obligatory for normal reproductive function immediately positioned kisspeptin as a major research target. Inactivating KISS1R mutations causes absent puberty and infertility. Activating mutations can cause precocious (early) puberty. ^(2,3) This established kisspeptin as the long-sought “gatekeeper” of the reproductive axis, controlling when and how the GnRH pulse generator fires.

Kisspeptin-10 is not FDA-approved for any therapeutic indication. It is investigational and used within research settings. Kisspeptin-54 has more advanced clinical trial data, including randomized controlled trials as an IVF oocyte-maturation trigger. ⁽⁴⁾ Kisspeptin-10 is not explicitly listed on the WADA Prohibited List by name, but may fall under the S0 (Non-Approved Substances) catch-all. ⁽⁵⁾ It was not included in the FDA Category 2 classification. ⁽⁶⁾ Healius supplies Kisspeptin-10 as a lyophilized (also referred to as lyophilized) powder in 5mg vials, intended strictly for laboratory and research applications.

Kisspeptin-10’s mechanism operates through a hierarchical signaling cascade that starts at the hypothalamus and cascades through the entire reproductive hormone axis. ^(1,2,3)

Step 1: Kisspeptin-10 binds to KISS1R (GPR54), a Gq/11-coupled receptor on GnRH neurons in the hypothalamus. This activates phospholipase C (PLC), generating IP3 and DAG, leading to intracellular calcium release and PKC activation, which depolarizes (also spelled depolarizes) the GnRH neuron. ^(2,3) Step 2: The depolarized GnRH neuron fires, releasing GnRH in a pulsatile pattern into the pituitary portal blood system. Step 3: GnRH binds to receptors on gonadotroph cells in the anterior pituitary, stimulating the release of LH and FSH. Step 4: LH and FSH act on the gonads: in men, LH stimulates Leydig cells to produce testosterone, and FSH supports spermatogenesis. In women, LH and FSH drive follicular development, estrogen production, and ultimately ovulation.

The critical distinction from direct GnRH analogs (like gonadorelin) is that kisspeptin acts upstream at KISS1R on GnRH neurons rather than directly at pituitary GnRH receptors. ^(2,3) This means kisspeptin preserves the body’s own pulsatile GnRH signaling rhythm. Direct GnRH agonists bypass the hypothalamus entirely and, with continuous administration, cause pituitary GnRH receptor desensitization that paradoxically suppresses the reproductive axis. Kisspeptin’s upstream mechanism avoids this desensitization risk when dosed appropriately.

The critical distinction from HCG (human chorionic gonadotropin) is that HCG mimics LH directly at gonadal receptors, bypassing both the hypothalamus and the pituitary. ⁽²⁾ Kisspeptin-10 stimulates the entire endogenous cascade from the top, producing physiological LH and FSH output rather than replacing it. This upstream approach is the fundamental pharmacological rationale for kisspeptin research in reproductive endocrinology.

Published clinical research on kisspeptin-10 includes direct human studies demonstrating its potent effects on the reproductive hormone axis. ^(1,3,4)

The landmark study by George et al.  ⁽²⁰¹¹⁾ in the Journal of Clinical Endocrinology and Metabolism investigated kisspeptin-10 in healthy men. ⁽¹⁾ IV bolus doses ranging from 0.01-3.0 mcg/kg produced a rapid, dose-dependent rise in serum LH, with maximal stimulation at 1 mcg/kg (LH rising from 4.1 to 12.4 IU/L at 30 minutes, a 2.5-fold increase). The 3 mcg/kg dose actually produced a reduced response compared to 1 mcg/kg, suggesting a bell-shaped dose-response curve, possibly due to rapid KISS1R desensitization at very high concentrations. ⁽¹⁾

A study by Jayasena et al. demonstrated sexual dimorphism in the effects of kisspeptin-10. In women, the LH and FSH responses varied across the menstrual cycle, with significantly greater sensitivity during the preovulatory phase than during the follicular phase. ⁽³⁾ This finding has important implications for female fertility research and IVF trigger timing.

Kisspeptin-54 (the longer form) has more advanced clinical trial data, including randomized (also spelled randomized) controlled trials, as an alternative to HCG for triggering oocyte maturation in IVF, with a potential safety advantage in reducing the risk of ovarian hyperstimulation syndrome (OHSS). ⁽⁴⁾ Because kisspeptin-10 and kisspeptin-54 share the same receptor and the same C-terminal binding sequence, kisspeptin-10 research benefits from the clinical validation established by kisspeptin-54 trials.

A 2025 PMC review on kisspeptins and fertility confirmed their “significant promise in restoring fertility” and noted ongoing studies in ovarian stimulation protocols and as cryoprotectants during vitrification. ⁽⁴⁾

Kisspeptin-10’s effects in men center on stimulating the LH/testosterone axis via the endogenous GnRH cascade. ^(1,2)

The George et al. study confirmed that kisspeptin-10 acutely increases LH secretion in healthy men, with testosterone following the LH rise over subsequent hours. ⁽¹⁾ This positions kisspeptin-10 as a research tool for studying natural testosterone production stimulation rather than exogenous testosterone replacement. Because kisspeptin acts upstream (in the hypothalamus), it preserves the entire HPG axis signaling chain, including FSH-driven spermatogenesis, which exogenous testosterone and even HCG do not fully replicate.

The “kisspeptin-10 vs HCG” comparison is frequently searched. HCG mimics LH directly at Leydig cell receptors, stimulating testosterone production without engaging the hypothalamus or pituitary. ⁽²⁾ Kisspeptin-10 stimulates the entire cascade from KISS1R through GnRH through LH to testosterone, preserving physiological feedback mechanisms. HCG does not stimulate FSH or support spermatogenesis through the natural pathway. For researchers studying preservation of testicular function (e.g., during TRT protocols), kisspeptin’s upstream mechanism may offer theoretical advantages over direct gonadotropin stimulation.

Research on testicular size is a notable search query. The rationale is that kisspeptin-10’s stimulation of endogenous LH and FSH may help maintain testicular volume in contexts where exogenous hormones suppress the HPG axis. Published clinical data specifically measuring testicular volume changes in response to kisspeptin-10 are limited, though the physiological mechanism supports the hypothesis.

Kisspeptin research in women focuses on ovulation triggering, fertility restoration, and the treatment of hypothalamic amenorrhoea (also spelled amenorrhea). ^(3,4)

The sexual dimorphism data from Jayasena et al. showed that women in the preovulatory phase of the menstrual cycle are significantly more sensitive to kisspeptin-10’s effects on LH and FSH release than those in the follicular phase. ⁽³⁾ This heightened sensitivity during the preovulatory window aligns with kisspeptin’s role in mediating the estrogen-induced LH surge that triggers ovulation.

Kisspeptin-54 has been evaluated in randomized controlled trials as an alternative IVF trigger to HCG. The potential advantage is reduced risk of ovarian hyperstimulation syndrome (OHSS), a serious complication of conventional IVF protocols, because kisspeptin triggers a more physiological LH surge through the endogenous pathway rather than providing a massive exogenous LH-like stimulus. ⁽⁴⁾

In functional hypothalamic amenorrhoea (loss of menstruation due to stress, low body weight, or excessive exercise), research has demonstrated that exogenous kisspeptin can restore GnRH pulsatility in women with impaired hypothalamic signaling. ⁽⁴⁾ This positions kisspeptin as a potential tool for reactivating the reproductive axis at the hypothalamic level, rather than bypassing it with downstream hormone replacement.

1. George JT et al. Kisspeptin-10 is a potent stimulator of LH and increases pulse frequency in men. J Clin Endocrinol Metab. 2011;96(8): E1228-E1236. PMID: 21632807. IV bolus 0.01-3.0 mcg/kg, 2.5-fold LH increase at 1 mcg/kg, bell-shaped dose-response, healthy men.

2. Exceed Enhancement. Kisspeptin-10 Research Guide: GPR54 Mechanism, Reproductive Axis, Studies. 2026. KNDy pulse generator, HPG axis regulation, KISS1R/Gq/11/PLC/IP3/Ca2+ signaling cascade, de Roux/Seminara 2003 landmark papers.

3. Jayasena CN et al. The effects of kisspeptin-10 on reproductive hormone release show sexual dimorphism in humans. PMC3232613. Women: heightened sensitivity during the preovulatory phase. Menstrual cycle-dependent response.

4. PMC12112093. Kisspeptins Regulating Fertility: Potential Future Therapeutic Approach in Infertility Treatment. 2025. KP10 half-life ~4 min, KP54 half-life ~28 min, IVF triggers, hypothalamic amenorrhoea, vitrification cryoprotectant research.

5. WADA Prohibited List 2026. Kisspeptin-10 is not explicitly listed. S0 (Non-Approved Substances) catch-all may apply.

6. FDA Category 2 Bulk Drug Substances. September 2023. Kisspeptin-10 is not listed.

This product is sold strictly for laboratory and research use only. It is not intended for human or animal consumption. It is not a dietary supplement, food, drug, or cosmetic. It is not intended to diagnose, treat, cure, or prevent any disease or condition. The buyer assumes all responsibility for the lawful use of this product in accordance with all applicable local, state, national, and international laws and regulations. By purchasing this product, the buyer confirms that they are a qualified researcher or are purchasing on behalf of a research institution.